Navigation Links
Edwards, Medtronic and Boston Scientific Lead Market Growth for Cardiac Surgery, Cardiac Rhythm Management and Interventional Cardiology Devices, Reports iData Research, Inc.
Date:10/29/2013

Vancouver, BC (PRWEB) October 29, 2013

iData Research, the leading global authority in medical device and pharmaceutical market research, has published a new report series for the U.S. Cardiology Device Markets. Cardiovascular disease is much more prevalent among patients over 55 years of age; therefore as the U.S. population ages, the incidence of cardiovascular disease will increase. In addition, rising rates of obesity will also contribute to the incidence of heart disease. As the baby boomer generation in the U.S. ages, the patient population will increase. This increase in the patient population will lead to an annual 3% to 4% increase in the number of patients requiring some type of arrhythmia treatment.

The fastest growing market among cardiac rhythm management, electrophysiology and ablation devices is diagnostic electrophysiology catheters. This market grew due to the increased use of Intracardiac Echography (ICE) and electrophysiology mapping catheters. The high average selling price of these products also bolstered market growth. Top competitors include Medtronic, St. Jude Medical and Boston Scientific.

The fastest growing areas of the cardiac surgery market will be that of transcatheter heart valve devices. These devices are used for repairing and replacing heart valves without the need for open surgery. They are expected to be widely accepted as new devices continue to be approved by the Food and Drug Administration (FDA). “The THVI market is expected to increase to represent over 15% of the total cardiac surgery market by 2019,” says Dr. Kamran Zamanian, CEO of iData. Competitors such as Edwards LifeSciences, Medtronic and Maquet together hold nearly half of the total market for cardiac surgery devices.

The U.S. market for interventional cardiology devices was valued at over $3.5 billion, with drug-eluting stents comprising the largest segment of the market, followed by coronary vascular closure devices, PTCA and cutting balloon catheters, bare-metal stents, intravascular ultrasound (IVUS) catheters, coronary introducer sheaths, interventional coronary guidewires, coronary embolic protection devices, interventional coronary catheters and balloon-inflation syringes. The report states that over the forecast period, the U.S. market for interventional cardiology is expected to exceed $4.2 billion by 2019 led by companies such as Boston Scientific, Abbott Laboratories, and St. Jude Medical. Market growth is expected to be tied to growth of the drug-eluting stent market and the expansion of the optical coherence tomography (OCT) catheter market.

In Addition to the U.S. cardiology report series, iData has research for the following countries: Japan, South Korea, China, India and Australia, Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, U.K.

For a free report synopsis, click here.

About iData Research

iData Research is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: infusion therapy, peripheral vascular, vascular-access, drug-delivery and more.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11278478.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Potential Medtronic Infusion Pump Malfunction Claims: Resource4thePeople Attorneys Now Providing Consulations
2. Medtronic Infuse Bone Graft Lawsuit Help: Resource4thePeople Reports New Court Ruling in Favor of Plaintiffs
3. Lawsuit Against Medtronic Inc. Will Proceed, as Judge Rejects Device Maker's Preemption Arguments to Have Medtronic Infuse Case Dismissed, Parker Waichman LLP Reports
4. Arizona Judge Rejects Medtronic Inc.'s Efforts to Dismiss a Lawsuit That Alleges the Company Promoted Off-Label Use of Its Infuse Bone Graft Product, Parker Waichman LLP Reports
5. Judge Denies Medtronic’s Bid to Dismiss Lawsuit Alleging that the Off-Label Usage of its Infuse Bone Growth Product Caused Disability, Parker Waichman LLP Notes
6. Access MediQuip's Rapid Response To Medtronic Infusion Pump Recall Protects Patients
7. Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments
8. Medtronic Neurostimulator: An Implantable Device Grants Warren Man New Lease on Life
9. Medtronic's InFuse Under Intense Scrutiny and Class Action Lawsuit
10. Medtronic Infuse Bone Graft Failure Allegation Lawsuits Update: New Legal Consultations Available Over Alleged Medical Malpractice
11. Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... Indianapolis, Indiana (PRWEB) , ... April 30, 2016 , ... ... USA Wrestling as they go for gold in Rio. Under the care of ... including two golds! , In an unprecedented showing, Maximized Living is sending the largest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology: